IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study

29 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

26 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

25 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Promising New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

17 May 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

16 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep to Participate in the JMP Securities Life Sciences Conference

09 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinoma

02 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

01 May 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

27 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Immutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meeting

26 Apr 2023 10:00:00 By Nasdaq GlobeNewswire

Immutep Appoints Dr. Florian Vogl as Chief Medical Officer

26 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting

17 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

31 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

30 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

23 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

14 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

30 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire